Find in Library

Even slight structural differences between phytocannabinoid isomers are usually enough to cause a change in their biological properties. In this study, we used in vitro CB1 agonism/antagonism assays to compare the receptor binding functionality of THCV (tetrahydrocannabivarin) and HHC (hexahydrocannabinol) isomers and applied molecular docking to provide an explanation for the difference in the activities. No CB1 agonism was observed for ∆9- and ∆8-THCV. Instead, both isomers antagonized CP 55940, with ∆9-THCV being approximately two times more potent than the ∆8 counterpart (IC₅₀ = 52.4 nM and 119.6 nM for ∆9- and ∆8-THCV, respectively). Docking simulations found two binding poses for THCV isomers, one very similar to ∆9-THC and one newly discovered pose involving the occupation of side pocket 1 of the CB1 receptor by the alkyl chain of the ligand. We suggested the latter as a potential antagonist pose. In addition, our results established 9<i>R</i>-HHC and 9<i>S</i>-HHC among partial agonists of the CB1 receptor. The 9<i>R</i>-HHC (EC₅₀ = 53.4 nM) isomer was a significantly more potent agonist than 9<i>S</i> (EC₅₀ = 624.3 nM). ∆9-THC and 9<i>R</i>-HHC showed comparable binding poses inside the receptor pocket, whereas 9<i>S</i>-HHC adopted a new and different binding posture that can explain its weak agonist activity.